IL17RC抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07048(IL17RC Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P07048(IL17RC Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Interleukin-17 receptor C (IL-17RC), a key component of the IL-17 receptor family, plays a critical role in mediating inflammatory and autoimmune responses. It forms a heterodimeric complex with IL-17RA, serving as the functional receptor for IL-17A and IL-17F, cytokines central to host defense and pathological inflammation. IL-17RC is expressed on epithelial cells, fibroblasts, and immune cells, where its activation triggers downstream signaling pathways, including NF-κB and MAPK, promoting the production of pro-inflammatory mediators like chemokines and antimicrobial peptides. Dysregulation of the IL-17/IL-17RC axis is implicated in autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease.

IL-17RC-targeting antibodies have emerged as therapeutic tools to modulate this pathway. These antibodies typically function by blocking IL-17A/F binding to IL-17RC, thereby inhibiting receptor activation and subsequent inflammatory cascades. Preclinical studies demonstrate their efficacy in reducing disease severity in animal models of psoriasis and arthritis. Clinical development has focused on autoimmune conditions, with some candidates progressing to early-phase trials. Challenges include optimizing receptor specificity to minimize off-target effects and balancing immunosuppression with infection risks. Research also explores diagnostic applications, as IL-17RC expression levels may correlate with disease activity. As understanding of IL-17RC's structural interactions grows, next-generation antibodies aim to achieve enhanced affinity and tailored pharmacokinetics, offering potential for personalized therapies in IL-17-driven disorders.